A Halifax-based law firm has launched a class-action lawsuit against Ottawa-area pot firm Canopy Growth (TSX:WEED) and its subsidiary Mettrum over recalls of medical marijuana that contained unauthorized pesticides.
In a statement of claim filed with Nova Scotia’s Supreme Court, Wagners alleges that Mettrum breached its contract with consumers and that its development, distribution and sale of medical marijuana was negligent.
Canopy Growth, Canada’s largest publicly traded medical marijuana producer, purchased Mettrum earlier this year.
(Sponsored)
Borden Ladner Gervais LLP and partners lead with generosity
Borden Ladner Gervais LLP (BLG) are no strangers to supporting charities in the nation’s capital. From the Boys & Girls Club of Ottawa to Crohn’s and Colitis Canada to the
OBJ launches the 2026 Executive Report on Cornwall
Cornwall has emerged as one of Eastern Ontario’s most compelling locations for business investment, thanks to a combination of affordability, strategic positioning, and a steadily growing economic base.
A spokesman for Smiths Falls-based Canopy Growth said Tuesday the company will “vigorously” defend itself against the lawsuit.
Lawyer Ray Wagner says representative plaintiff Neal Partington, a house painter from Nova Scotia, says he suffered severe nausea and vomiting over the six months that he was taking Mettrum products to deal with symptoms of an injury.
Wagner says it could take six to eight months before the court decides whether to certify the class-action lawsuit.
The allegations in the statement of claim have not been proven in court.
Canopy Growth CEO Bruce Linton has said that the use of unregistered pest control products was “inexcusable” but that Health Canada had determined the pesticide wasn’t likely to cause any adverse health consequences.
